⁶⁸Ga-DPA in the Lung Cancer Diagnosis

Clinical Application of PD-L1 Targeted Imaging Agent ⁶⁸Ga-DPA in the Diagnosis of Lung Cancer

Status

Enrolling by invitation

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07023068

Enrollment

Registered

2025-06-15

Start date

2024-09-28

Completion date

2027-09-28

Last updated

2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancers

Keywords

PD-L1, lung cancer, PET/CT

Brief summary

In previous studies, we synthesized a PD-L1-targeted molecular probe, ⁶⁸Ga-DPA, and developed a ⁶⁸Ga-DPA injection for clinical research. Preliminary studies demonstrated its favorable safety profile and excellent imaging performance. Leveraging the established strengths of the Department of Nuclear Medicine at Peking Union Medical College Hospital, we now plan to conduct an exploratory PET/CT imaging study in lung cancer patients. This study aims to provide an in vivo, non-invasive, and visualizable technique for detecting PD-L1 expression levels and spatial distribution in tumors. It will further validate the clinical utility of this technology, offering critical diagnostic insights for initial assessment and treatment efficacy evaluation in PD-L1-positive tumor patients undergoing PD-L1-targeted therapies.

Interventions

DIAGNOSTIC_TEST68Ga-DPA PET/CT

Use 68Ga-DPA PET/CT in the diagnosis of lung cancer

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Age ≥18 years, regardless of gender. * Patients clinically confirmed or suspected of lung cancer, with pathological specimens obtainable via biopsy or surgery within the recent 2 months. * At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * Expected survival \>3 months.

Exclusion criteria

* Severe hepatic or renal dysfunction (serum creatinine \>3.0 mg/dL or any liver enzyme level ≥5× upper limit of normal). * Women who are planning pregnancy, pregnant, or breastfeeding. * Inability to lie supine for 30 minutes. * Claustrophobia or other psychiatric disorders. * Intolerance to any clinical procedures in the study. * Other conditions deemed ineligible by the investigator.

Design outcomes

Primary

Measure	Time frame	Description
SUV	0-180 minutes post-injection	measured by PET/CT

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026